Eris Lifesciences recently announced that its Board of Directors has approved the acquisition of the remaining three percent stake in Swiss Parenterals, a subsidiary. The proposed transaction will be effected as a share swap, i.e. through a preferential issuance of Eris equity shares to the seller Naishadh Shah, thereby making him a top-10 shareholder of Eris and an integral part of Eris’ senior management team with long-term alignment.

Commenting on the acquisition, Amit Bakshi, Chairman and Managing Director, Eris Lifesciences, said, “On behalf of the shareholders of Eris, I am delighted to welcome Mr Naishadh Shah to the community of Erisians. I am also happy to share that we propose to designate him as the Managing Director of Swiss Parenterals. FY27 promises to be a breakout year for our international business and Naishadh’s continued leadership and stewardship will be pivotal to its growth.”

Adding to it, Naishadh Shah, Wholetime Director, Swiss Parenterals, also expressed his views on this acquisition.

“It is exciting to get aligned with Eris as a long-term shareholder and senior management. The Eris platform, with its manufacturing capabilities in Ahmedabad and Bhopal, combined with the existing Swiss facilities, will significantly augment our value proposition to our global clientele. I look forward to the next leg of this growth journey,” he said.